HER2

Summary

Gene Symbol: HER2
Description: erb-b2 receptor tyrosine kinase 2
Alias: CD340, HER-2, HER-2/neu, HER2, MLN 19, NEU, NGL, TKR1, receptor tyrosine-protein kinase erbB-2, c-erb B2/neu protein, herstatin, human epidermal growth factor receptor 2, metastatic lymph node gene 19 protein, neuro/glioblastoma derived oncogene homolog, neuroblastoma/glioblastoma derived oncogene homolog, p185erbB2, proto-oncogene Neu, proto-oncogene c-ErbB-2, tyrosine kinase-type cell surface receptor HER2, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2, v-erb-b2 avian erythroblastic leukemia viral oncoprotein 2, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog
Species: human
Products:     HER2

Top Publications

  1. Lamy P, Fina F, Bascoul Mollevi C, Laberenne A, Martin P, Ouafik L, et al. Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers. Breast Cancer Res. 2011;13:R15 pubmed publisher
    b>Human epidermal growth factor receptor 2 (HER2)-amplified breast cancers represent a tumor subtype with chromosome 17q rearrangements that lead to frequent gene amplifications...
  2. Andersson U, Schwartzbaum J, Wiklund F, Sjöström S, Liu Y, Tsavachidis S, et al. A comprehensive study of the association between the EGFR and ERBB2 genes and glioma risk. Acta Oncol. 2010;49:767-75 pubmed publisher
    ..Further studies are required to reinvestigate these findings and evaluate the functional significance. ..
  3. Saglam S, Suzme R, Gurdol F. Serum tumor necrosis factor-alpha and interleukin-2 concentrations in newly diagnosed ERBB2 (HER2/neu) positive breast cancer patients. Int J Biol Markers. 2009;24:142-6 pubmed
    ..Overexpression of ERBB2 (c-erb-b2; formerly HER2/neu), which is a member of the epidermal growth receptor family, is associated with involvement of lymph nodes, ..
  4. Ingold Heppner B, Behrens H, Balschun K, Haag J, Krüger S, Becker T, et al. HER2/neu testing in primary colorectal carcinoma. Br J Cancer. 2014;111:1977-84 pubmed publisher
    Anti-HER2/neu therapy is well-established in breast and gastric carcinoma. The increased understanding of this pathway led to the identification of new promising drugs in addition to trastuzumab, offering further perspectives...
  5. Lerdrup M, Bruun S, Grandal M, Roepstorff K, Kristensen M, Hommelgaard A, et al. Endocytic down-regulation of ErbB2 is stimulated by cleavage of its C-terminus. Mol Biol Cell. 2007;18:3656-66 pubmed
    ..Altogether, we suggest that geldanamycin leads to C-terminal cleavage of ErbB2, which releases the receptor from a retention mechanism and causes endocytosis and lysosomal degradation of ErbB2. ..
  6. Fijołek J, Wiatr E, Rowinska Zakrzewska E, Giedronowicz D, Langfort R, Chabowski M, et al. p53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer. Int J Biol Markers. 2006;21:81-7 pubmed
    The aim of the study was to investigate a relation between p53 and HER2/neu expression in resected lung tumors and the response of those tumors to neoadjuvant chemotherapy...
  7. Ghayad S, Vendrell J, Ben Larbi S, Dumontet C, Bieche I, Cohen P. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer. 2010;126:545-62 pubmed publisher
    ..In conclusion, the combination of MAPK and PI3K inhibitors represents a promising strategy to overcome endocrine therapy resistance in ER+ breast cancer patients. ..
  8. Haslekås C, Breen K, Pedersen K, Johannessen L, Stang E, Madshus I. The inhibitory effect of ErbB2 on epidermal growth factor-induced formation of clathrin-coated pits correlates with retention of epidermal growth factor receptor-ErbB2 oligomeric complexes at the plasma membrane. Mol Biol Cell. 2005;16:5832-42 pubmed
  9. Lang J, Mosalpuria K, Cristofanilli M, Krishnamurthy S, Reuben J, Singh B, et al. HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. Breast Cancer Res Treat. 2009;113:501-7 pubmed publisher
    ..0 CTC per CTC positive patient (range 1-22). HER2 status was the sole primary tumor characteristic that reliably predicted the presence of CTCs (P = 0...

More Information

Publications446 found, 100 shown here

  1. Aertgeerts K, Skene R, Yano J, Sang B, Zou H, Snell G, et al. Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein. J Biol Chem. 2011;286:18756-65 pubmed publisher
    Aberrant signaling of ErbB family members human epidermal growth factor 2 (HER2) and epidermal growth factor receptor (EGFR) is implicated in many human cancers, and HER2 expression is predictive of human disease recurrence and prognosis...
  2. Papadopoulou E, Tripsianis G, Anagnostopoulos K, Tentes I, Kakolyris S, Galazios G, et al. Significance of serum tumor necrosis factor-alpha and its combination with HER-2 codon 655 polymorphism in the diagnosis and prognosis of breast cancer. Int J Biol Markers. 2010;25:126-35 pubmed
    ..The present study was conducted to clarify the diagnostic and prognostic significance of TNF-alpha and its combination with HER-2 Ile655Val SNP in breast cancer...
  3. Sun T, Aceto N, Meerbrey K, Kessler J, Zhou C, Migliaccio I, et al. Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell. 2011;144:703-18 pubmed publisher
    ..PTPN12 suppresses transformation by interacting with and inhibiting multiple oncogenic tyrosine kinases, including HER2 and EGFR...
  4. Liu P, Cleveland T, Bouyain S, Byrne P, Longo P, Leahy D. A single ligand is sufficient to activate EGFR dimers. Proc Natl Acad Sci U S A. 2012;109:10861-6 pubmed publisher
    ..of epidermal growth factor (EGF) binding to EGFR and the behavior of the ligandless EGFR homolog ErbB2/HER2, however...
  5. Saghatchian M, Guepratte S, Hacene K, Neumann R, Floiras J, Pichon M. Serum HER-2 extracellular domain: relationship with clinicobiological presentation and prognostic value before and after primary treatment in 701 breast cancer patients. Int J Biol Markers. 2004;19:14-22 pubmed
    ..To determine the clinical correlations and prognostic value of serum HER-2 (sHER-2) before and after primary breast cancer treatment...
  6. Kunz P, Mojtahed A, Fisher G, Ford J, Chang D, Balise R, et al. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol Morphol. 2012;20:13-24 pubmed publisher
    Recent evidence suggests that trastuzumab, a monoclonal antibody which targets HER2, in combination with chemotherapy is a therapeutic option in patients with HER2-positive gastric or gastroesophageal junction cancer...
  7. Varis A, Zaika A, Puolakkainen P, Nagy B, Madrigal I, Kokkola A, et al. Coamplified and overexpressed genes at ERBB2 locus in gastric cancer. Int J Cancer. 2004;109:548-53 pubmed
    ..Additional studies are required to thoroughly understand the biological significance of these genes in gastric cancer. ..
  8. Ghaderi A, Vasei M, Maleck Hosseini S, Gharesi Fard B, Khodami M, Doroudchi M, et al. The expression of c-erbB-1 and c-erbB-2 in Iranian patients with gastric carcinoma. Pathol Oncol Res. 2002;8:252-6 pubmed
    ..Moreover, the relatively high percentage of c-erbB-2 positive tumors may provide a useful target for the immunotherapy of these cancers. ..
  9. Sircoulomb F, Bekhouche I, Finetti P, Adélaïde J, Ben Hamida A, Bonansea J, et al. Genome profiling of ERBB2-amplified breast cancers. BMC Cancer. 2010;10:539 pubmed publisher
    ..We have shown that ER+ and ER- ERBB2-amplified BCs are different, distinguished ERBB2 amplicons in IBC and non-IBC, and identified genomic features that may be useful in the design of alternative therapeutical strategies. ..
  10. Badzek S, Kelović V, Plestina S, Humar I, Veir Z, Mihaljević Z. Serum HER2/ECD value in stage I and II early breast cancer: need of a lower cut-off?. Wien Klin Wochenschr. 2011;123:726-31 pubmed publisher
    b>HER2 overexpression is well-established risk factor of worse prognosis in metastatic and early breast cancer...
  11. Riethdorf S, Muller V, Zhang L, Rau T, Loibl S, Komor M, et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res. 2010;16:2634-45 pubmed publisher
    ..with capecitabine, or docetaxel followed by capecitabine) and additional trastuzumab treatment for patients with HER2-positive tumors...
  12. Diehl K, Grewal N, Ethier S, Woods Ignatoski K. p38MAPK-activated AKT in HER-2 overexpressing human breast cancer cells acts as an EGF-independent survival signal. J Surg Res. 2007;142:162-9 pubmed
    ..The data presented here indicate that AKT activation can compensate for EGF-mediated cell survival signals leading to growth factor independence and anchorage-independent growth. ..
  13. Treekitkarnmongkol W, Suthiphongchai T. High expression of ErbB2 contributes to cholangiocarcinoma cell invasion and proliferation through AKT/p70S6K. World J Gastroenterol. 2010;16:4047-54 pubmed
    ..Our data indicated that high ErbB2 expression enhances CCA invasion, motility and proliferation via the AKT/p70S6K pathway, which suggests the possibility of targeting these molecules for CCA therapy. ..
  14. Essapen S, Thomas H, Green M, De Vries C, Cook M, Marks C, et al. The expression and prognostic significance of HER-2 in colorectal cancer and its relationship with clinicopathological parameters. Int J Oncol. 2004;24:241-8 pubmed
    ..In addition, high levels of membraneous HER-2 in colorectal cancer could make HER-2 a good target for monoclonal antibody-based immunotherapy. ..
  15. Shen F, Lin Q, Childress C, Yang W. Identification of the domain in ErbB2 that restricts ligand-induced degradation. Cell Signal. 2008;20:779-86 pubmed publisher
  16. Offersen B, Alsner J, Ege Olsen K, Riisbro R, Brunner N, Sørensen F, et al. A comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer. Acta Oncol. 2008;47:618-32 pubmed publisher
    The prognostic potential of HER2, TP53 mutations, PAI-1 protein levels, angiogenesis and proliferation were investigated in tumours from 408 patients with early breast cancer followed >10 years...
  17. Yan B, Yau E, Bte Omar S, Ong C, Pang B, Yeoh K, et al. A study of HER2 gene amplification and protein expression in gastric cancer. J Clin Pathol. 2010;63:839-42 pubmed publisher
    ..b>HER2 has been identified as a potential candidate for targeted therapy in gastric cancers displaying HER2 gene ..
  18. Yan S, Hu Y, Fan J, Tao G, Lu Y, Cai X, et al. Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma. World J Gastroenterol. 2011;17:1501-6 pubmed publisher
    ..Clinicopathologic data about all patients were collected. The levels of HER-2 3+, HER-2 2+ and HER2 1+ were measurable in 6.9%, 8.3% and 17.2% of the samples, respectively. No HER-2 was stained in 67...
  19. Li N, Lu H, Chen C, Bu X, Huang P. Loss of fatty acid synthase inhibits the "HER2-PI3K/Akt axis" activity and malignant phenotype of Caco-2 cells. Lipids Health Dis. 2013;12:83 pubmed publisher
    ..In this study, our aims were to explore the role of FASN in regulating the "HER2-PI3K/Akt axis" activity and malignant phenotype of colorectal cancer...
  20. Pappas A, Lagoudianakis E, Seretis C, Tsiambas E, Koronakis N, Toutouzas K, et al. Clinical role of HER-2/neu expression in colorectal cancer. J BUON. 2013;18:98-104 pubmed
    To evaluate the HER-2/neu expression and its relationship with clinicopathological parameters and prognosis in colorectal cancer patients...
  21. Ramsauer V, Carraway C, Salas P, Carraway K. Muc4/sialomucin complex, the intramembrane ErbB2 ligand, translocates ErbB2 to the apical surface in polarized epithelial cells. J Biol Chem. 2003;278:30142-7 pubmed
    ..The ability of Muc4/SMC to alter the localization of ErbB2, particularly a phosphorylated form of it, in epithelial cells, suggests that it has an important role in regulating ErbB2 signaling. ..
  22. Ruschoff J, Nagelmeier I, Baretton G, Dietel M, Hofler H, Schildhaus H, et al. [Her2 testing in gastric cancer. What is different in comparison to breast cancer?]. Pathologe. 2010;31:208-17 pubmed publisher
    ..Only patients with tumors which over express Her2 as defined by IHC2+ and a confirmatory FISH+ result, or IHC 3+, determined by an accurate and validated assay are ..
  23. Diermeier Daucher S, Breindl S, Buchholz S, Ortmann O, Brockhoff G. Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors. Cytometry A. 2011;79:684-93 pubmed publisher
    ..of monoclonal antibodies and small molecule inhibitors emerged as potent therapeutic agents in the treatment of Her2/neu overexpressing breast cancer...
  24. Monego G, Arena V, Maggiano N, Costarelli L, Crescenzi A, Zelano G, et al. Borderline HER-2 breast cancer cases: histochemical versus real-time PCR analysis and impact of different cut-off values. Scand J Clin Lab Invest. 2007;67:402-12 pubmed
    ..Finally, above certain in-lab generated threshold values, PCR might be proposed as a highly predictive positive test in HER-2 assessment. ..
  25. Zhu J, Chen R, Yi W, Cantin G, Fearns C, Yang Y, et al. Protein tyrosine phosphatase PTPN13 negatively regulates Her2/ErbB2 malignant signaling. Oncogene. 2008;27:2525-31 pubmed
    Deregulated Her2/ErbB2 receptor tyrosine kinase drives tumorigenesis and tumor progression in a variety of human tissues. Her2 transmits oncogenic signals through phosphorylation of its cytosolic domain...
  26. Gritzapis A, Voutsas I, Lekka E, Tsavaris N, Missitzis I, Sotiropoulou P, et al. Identification of a novel immunogenic HLA-A*0201-binding epitope of HER-2/neu with potent antitumor properties. J Immunol. 2008;181:146-54 pubmed
    HER-2/neu oncoprotein is overexpressed in a variety of human tumors and is associated with aggressive disease...
  27. Tovey S, Brown S, Doughty J, Mallon E, Cooke T, Edwards J. Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. Br J Cancer. 2009;100:680-3 pubmed publisher
    We present a retrospective analysis on a cohort of low-grade, node-negative patients showing that human epidermal growth factor receptor 2 (HER2) status significantly affects the survival in this otherwise very good prognostic group...
  28. Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J, et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature. 2004;431:525-6 pubmed
    ..We have sequenced the gene encoding the transmembrane protein tyrosine kinase ERBB2 (also known as HER2 or Neu) from 120 primary lung tumours and identified 4% that have mutations within the kinase domain; in the ..
  29. Mayr D, Kanitz V, Amann G, Engel J, Burges A, Löhrs U, et al. HER-2/neu gene amplification in ovarian tumours: a comprehensive immunohistochemical and FISH analysis on tissue microarrays. Histopathology. 2006;48:149-56 pubmed
    Data on HER-2/neu overexpression, its correlation to prognosis and the success of treatment with Herceptin((R)) in ovarian carcinomas are scarce and contradictory...
  30. Kang L, Guo Y, Zhang X, Meng J, Wang Z. A positive cross-regulation of HER2 and ER-?36 controls ALDH1 positive breast cancer cells. J Steroid Biochem Mol Biol. 2011;127:262-8 pubmed publisher
    ..in these cells using the shRNA method diminished their responsiveness to estrogen and significantly down-regulated HER2 expression...
  31. Park D, Kang M, Oh S, Kim H, Cho Y, Sohn C, et al. HER-2/neu overexpression is an independent prognostic factor in colorectal cancer. Int J Colorectal Dis. 2007;22:491-7 pubmed
    The HER-2/neu protein is intimately involved with normal cell proliferation and tissue growth, as it is extensively homologous and is related to the epidermal growth factor receptor...
  32. Tanizaki J, Okamoto I, Takezawa K, Tsukioka S, Uchida J, Kiniwa M, et al. Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification. Mol Cancer Ther. 2010;9:1198-207 pubmed publisher
    Amplification of human epidermal growth factor receptor 2 (HER2) has been detected in 20% to 30% of gastric cancers and is associated with a poor outcome...
  33. Wallasch C, Weiss F, Niederfellner G, Jallal B, Issing W, Ullrich A. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J. 1995;14:4267-75 pubmed
    Amplification and/or overexpression of HER2/neu and HER3 genes have been implicated in the development of cancer in humans...
  34. Sahlberg K, Hongisto V, Edgren H, Mäkelä R, Hellström K, Due E, et al. The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells. Mol Oncol. 2013;7:392-401 pubmed publisher
    About 20% of breast cancers are characterized by amplification and overexpression of the HER2 oncogene...
  35. Fehm T, Muller V, Aktas B, Janni W, Schneeweiss A, Stickeler E, et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat. 2010;124:403-12 pubmed publisher
    There is a growing body of evidence that HER2 status can change during disease recurrence or progression in breast cancer patients...
  36. Fabi A, Di Benedetto A, Metro G, Perracchio L, Nistico C, Di Filippo F, et al. HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care. Clin Cancer Res. 2011;17:2055-64 pubmed publisher
    To analyze HER2 status in primary breast cancer (PBC) compared with correspondent metachronous metastases and to investigate whether BC phenotype may be predictive of change in HER2 expression...
  37. Grabsch H, Sivakumar S, Gray S, Gabbert H, Müller W. HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. Cell Oncol. 2010;32:57-65 pubmed publisher
    ..Existing data on HER2 expression and its clinical relevance in GC are still limited and controversial...
  38. Adachi R, Horiuchi S, Sakurazawa Y, Hasegawa T, Sato K, Sakamaki T. ErbB2 down-regulates microRNA-205 in breast cancer. Biochem Biophys Res Commun. 2011;411:804-8 pubmed publisher
    Gene amplification and protein overexpression of erbB2 (Her2/neu) has been observed in approximately 20-30% of breast cancers...
  39. Wolstenholme V, Hawkins M, Ashley S, Tait D, Ross G. HER2 significance and treatment outcomes after radiotherapy for brain metastases in breast cancer patients. Breast. 2008;17:661-5 pubmed publisher
    The aim of this retrospective study was to examine the influence of HER2 status on outcome in breast cancer patients following whole brain radiotherapy (WBRT) for cerebral metastases...
  40. Lennon S, Barton C, Banken L, Gianni L, Marty M, Baselga J, et al. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer. J Clin Oncol. 2009;27:1685-93 pubmed publisher
    Trastuzumab is a humanized monoclonal antibody directed against human epidermal growth factor receptor 2 (HER2)...
  41. Begnami M, Fukuda E, Fregnani J, Nonogaki S, Montagnini A, da Costa W, et al. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J Clin Oncol. 2011;29:3030-6 pubmed publisher
    The human epidermal growth factor receptor (HER) family consists of four members: ErbB-1 (HER1), ErbB-2 (HER2), ErbB-3 (HER3), and ErbB-4 (HER4)...
  42. Soysal S, Muenst S, Barbie T, Fleming T, Gao F, Spizzo G, et al. EpCAM expression varies significantly and is differentially associated with prognosis in the luminal B HER2(+), basal-like, and HER2 intrinsic subtypes of breast cancer. Br J Cancer. 2013;108:1480-7 pubmed publisher
    ..intrinsic subtypes, EpCAM expression was associated with an unfavourable prognosis in the basal-like and luminal B HER2(+) subtypes but associated with a favourable prognosis in the HER2 subtype...
  43. Tong S, Ha S, Ki K, Lee J, Lee S, Lee K, et al. The effects of obesity and HER-2 polymorphisms as risk factors for endometrial cancer in Korean women. BJOG. 2009;116:1046-52 pubmed publisher
    ..Endometrial cancer risk increased significantly in proportion to BMI. However, HER-2 polymorphism did not affect significantly on the risk of endometrial cancer. ..
  44. Zhan N, Dong W, Tang Y, Wang Z, Xiong C. Analysis of HER2 gene amplification and protein expression in esophageal squamous cell carcinoma. Med Oncol. 2012;29:933-40 pubmed publisher
    The HER2 gene, which is located on chromosomes 17, is a therapeutic target for cancer. Amplification of HER2 has been described in several tumor types...
  45. Choi J, Han H, Lee H, Lee O, Kim J, Lim S, et al. Positive response to trastuzumab in a case of HER2-overexpressing metastatic gastric cancer that presented as severe thrombocytopenia. Onkologie. 2011;34:621-4 pubmed publisher
    Trastuzumab, a humanized monoclonal antibody directed against human epidermal growth factor receptor 2 (HER2), has been shown to be active against metastatic gastric cancers that overexpress HER2...
  46. Ignatiadis M, Rothé F, Chaboteaux C, Durbecq V, Rouas G, Criscitiello C, et al. HER2-positive circulating tumor cells in breast cancer. PLoS ONE. 2011;6:e15624 pubmed publisher
    ..To interrogate dissemination in BC, we studied CTCs and HER2 expression on CTCs across the spectrum of BC staging...
  47. Ross J, Fletcher J, Linette G, Stec J, Clark E, Ayers M, et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist. 2003;8:307-25 pubmed
    The HER-2/neu oncogene encodes a transmembrane tyrosine kinase receptor with extensive homology to the epidermal growth factor receptor...
  48. Villman K, Sjöström J, Heikkilä R, Hultborn R, Malmström P, Bengtsson N, et al. TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer. Acta Oncol. 2006;45:590-6 pubmed
    The purpose of this study was to evaluate amplification of topoisomerase IIalpha (TOP2A) and HER2 genes as predictors of response to chemotherapy in advanced breast cancer...
  49. Brunelli M, Manfrin E, Martignoni G, Miller K, Remo A, Reghellin D, et al. Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria. Am J Clin Pathol. 2009;131:678-82 pubmed publisher
    We evaluated intratumoral heterogeneity of 30 ductal breast carcinomas with HER2/neu amplification, scored by the American Society of Clinical Oncology/ College of American Pathologists (ASCO/CAP) criteria, and 3+ immunoexpression...
  50. Menard S, Casalini P, Campiglio M, Pupa S, Tagliabue E. Role of HER2/neu in tumor progression and therapy. Cell Mol Life Sci. 2004;61:2965-78 pubmed
    b>HER2 (human epidermal growth factor receptor-2; also known as erbB2) and its relatives HER1 (epidermal growth factor receptor; EGFR), HER3 and HER4 belong to the HER family of receptor tyrosine kinases...
  51. Ding Y, Liu Z, Desai S, Zhao Y, Liu H, Pannell L, et al. Receptor tyrosine kinase ErbB2 translocates into mitochondria and regulates cellular metabolism. Nat Commun. 2012;3:1271 pubmed publisher
    ..Our study provides a novel perspective on the metabolic regulatory function of ErbB2 and reveals that mtErbB2 has an important role in the regulation of cellular metabolism and cancer cell resistance to therapeutics. ..
  52. Marks J, McLellan M, Zakowski M, Lash A, Kasai Y, Broderick S, et al. Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. PLoS ONE. 2007;2:e426 pubmed
    ..e., EGFR, HER2/ERBB2, HER4/ERBB4, PIK3CA, BRAF, and KRAS...
  53. Scott G, Marx C, Berger C, Saunders L, Verdin E, Schafer S, et al. Destabilization of ERBB2 transcripts by targeting 3' untranslated region messenger RNA associated HuR and histone deacetylase-6. Mol Cancer Res. 2008;6:1250-8 pubmed publisher
  54. Kong Y, Dai S, Xie X, Xiao X, Lv N, Guo J, et al. High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients. J Cancer Res Clin Oncol. 2012;138:275-84 pubmed publisher
    High serum human epidermal growth factors receptor-2 (HER2) extracellular domain (ECD) has been identified as an independent prognostic indicator of poor prognosis in metastatic breast cancer...
  55. Tomizawa K, Suda K, Onozato R, Kosaka T, Endoh H, Sekido Y, et al. Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. Lung Cancer. 2011;74:139-44 pubmed publisher
    Activating mutation in the kinase domain of the human EGF receptor 2 (HER2) gene (also known as ERBB2 or neu) is reported to be present in a small fraction of lung adenocarcinomas...
  56. Xia W, Petricoin E, Zhao S, Liu L, Osada T, Cheng Q, et al. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models. Breast Cancer Res. 2013;15:R85 pubmed
    The human epidermal growth factor receptor 2 (HER2) receptor tyrosine kinase (RTK) oncogene is an attractive therapeutic target for the treatment of HER2-addicted tumors...
  57. Siziopikou K, Khan S. Correlation of HER2 gene amplification with expression of the apoptosis-suppressing genes bcl-2 and bcl-x-L in ductal carcinoma in situ of the breast. Appl Immunohistochem Mol Morphol. 2005;13:14-8 pubmed
    The protein product of the HER2 oncogene is overexpressed in an estimated 25 to 30% of breast carcinomas and is considered an indicator of poor clinical outcome...
  58. Susini T, Bussani C, Marini G, Nori J, Olivieri S, Molino C, et al. Preoperative assessment of HER-2/neu status in breast carcinoma: the role of quantitative real-time PCR on core-biopsy specimens. Gynecol Oncol. 2010;116:234-9 pubmed publisher
    Knowledge of HER-2/neu status is mandatory to identify breast cancer patients amenable to trastuzumab treatment...
  59. McDonagh C, Huhalov A, Harms B, Adams S, Paragas V, Oyama S, et al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Ther. 2012;11:582-93 pubmed publisher
    ..MM-111 can be rationally combined with trastuzumab or lapatinib for increased antitumor activity and may in the future complement existing ErbB2-directed therapies to treat resistant tumors or deter relapse. ..
  60. Di Leo A, Desmedt C, Bartlett J, Piette F, Ejlertsen B, Pritchard K, et al. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol. 2011;12:1134-42 pubmed publisher
    ..We aimed to assess the value of HER2 and TOP2A as predictive markers of response to anthracycline-based adjuvant therapy in patients with early breast ..
  61. An H, Kim N, Oh D, Kim S, Park M, Jung M, et al. Her2 genotype and breast cancer progression in Korean women. Pathol Int. 2005;55:48-52 pubmed
    The amplification and overexpression of Her2 proto-oncogene have been found to be associated with the development and progression of human breast cancer...
  62. Tikhomirov O, Carpenter G. Identification of ErbB-2 kinase domain motifs required for geldanamycin-induced degradation. Cancer Res. 2003;63:39-43 pubmed
    The ansamycin antibiotic geldanamycin (GA) induces the intracellular degradation of ErbB-2/neu. Degradation of ErbB-2 proceeds through cleavage(s) within the kinase domain, resulting in the formation of a 135 kDa ectodomain fragment and ..
  63. Geradts J, Bean S, Bentley R, Barry W. The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features. Cancer Invest. 2010;28:969-77 pubmed publisher
    ..was correlated with six pathobiologic features: estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status, and the three components of the Nottingham tumor grade...
  64. Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011;1:508-23 pubmed publisher
    ..Genotype-response correlations indicated HER2 amplification specifically in a subset of cetuximab-resistant, KRAS/NRAS/BRAF/PIK3CA wild-type cases...
  65. Zhao Y, Zhou M, Liu H, Ding Y, Khong H, Yu D, et al. Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth. Oncogene. 2009;28:3689-701 pubmed publisher
    ..This pathway may have a major role in regulating glucose metabolism in breast cancer cells. These novel findings have important implications for the design of new approaches to target ErbB2-overexpressing breast cancers. ..
  66. Moulder S, Yakes F, Muthuswamy S, Bianco R, Simpson J, Arteaga C. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res. 2001;61:8887-95 pubmed
    Aberrrant signaling by the epidermal growth factor receptor [EGFR (HER1, erbB1)] and/or HER2/neu tyrosine kinases is present in a cohort of breast carcinomas...
  67. Penuel E, Akita R, Sliwkowski M. Identification of a region within the ErbB2/HER2 intracellular domain that is necessary for ligand-independent association. J Biol Chem. 2002;277:28468-73 pubmed
    ..A well characterized mutant of the rodent ortholog neu involves substitution of glutamate for valine within the transmembrane domain...
  68. Leary A, Hanna W, van de Vijver M, Penault Llorca F, Ruschoff J, Osamura R, et al. Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients. J Clin Oncol. 2009;27:1694-705 pubmed publisher
    ..This conclusion is in agreement with the 2007 American Society of Clinical Oncology guidelines on the use of biomarkers in breast cancer. ..
  69. Wu S, Cheng T, Chen W, Shyu H, Ko C, Huang H, et al. Matriptase is involved in ErbB-2-induced prostate cancer cell invasion. Am J Pathol. 2010;177:3145-58 pubmed publisher
    ..In summary, our data indicate that ErbB-2 signaling via the phosphatidylinositol 3-kinase pathway results in up-regulated matriptase zymogen activity, which contributes to PCa cell invasion. ..
  70. Yu M, Lin G, Arshadi N, Kalatskaya I, Xue B, Haider S, et al. Expression profiling during mammary epithelial cell three-dimensional morphogenesis identifies PTPRO as a novel regulator of morphogenesis and ErbB2-mediated transformation. Mol Cell Biol. 2012;32:3913-24 pubmed publisher
    ..Furthermore, we showed that the receptor tyrosine kinase ErbB2/HER2 is a direct substrate of PTPRO and that loss of PTPRO increased ErbB2-induced cell proliferation and transformation,..
  71. Khan A, King B, Smith B, Smith G, Digiovanna M, Carter D, et al. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. Clin Cancer Res. 2002;8:540-8 pubmed
    The role of HER-2/neu in squamous cell carcinoma (SCC) of the head and neck is not well defined...
  72. Bargmann C, Hung M, Weinberg R. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature. 1986;319:226-30 pubmed
    The neu oncogene is repeatedly activated in neuro- and glioblastomas derived by transplacental mutagenesis of the BDIX strain of rat with ethylnitrosourea...
  73. Adam L, Vadlamudi R, Kondapaka S, Chernoff J, Mendelsohn J, Kumar R. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J Biol Chem. 1998;273:28238-46 pubmed
    ..We also demonstrated that HRG stimulation promoted physical interactions between PAK1, actin, and human epidermal growth factor receptor 2 (HER2) receptors, and these interactions were dependent on the activation of PI-3 kinase...
  74. Seol H, Lee H, Choi Y, Lee H, Kim Y, Kim J, et al. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. Mod Pathol. 2012;25:938-48 pubmed publisher
    Intratumoral heterogeneity of human epidermal growth factor receptor 2 (HER2) gene amplification has been reported to occur with variable frequencies in breast cancers...
  75. Morrison L, Jewell S, Usha L, Blondin B, Rao R, Tabesh B, et al. Effects of ERBB2 amplicon size and genomic alterations of chromosomes 1, 3, and 10 on patient response to trastuzumab in metastatic breast cancer. Genes Chromosomes Cancer. 2007;46:397-405 pubmed
    ..These results suggest that patient selection for trastuzumab may be improved by considering ERBB2 amplicon size and genomic status of the 1q25, PTGS2, and centromere 10 loci. ..
  76. Lee Hoeflich S, Crocker L, Yao E, Pham T, Munroe X, Hoeflich K, et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 2008;68:5878-87 pubmed publisher
    Epidermal growth factor receptor (EGFR) and HER3 each form heterodimers with HER2 and have independently been implicated as key coreceptors that drive HER2-amplified breast cancer...
  77. Chia S, Norris B, Speers C, Cheang M, Gilks B, Gown A, et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol. 2008;26:5697-704 pubmed publisher
    b>Human epidermal growth factor receptor 2 gene (HER2) is associated with a poorer outcome in node-positive breast cancer, but the results are conflicting in node-negative disease...
  78. Mittendorf E, Tucker S, McKenzie T, Qiao N, Akli S, Biernacka A, et al. A novel interaction between HER2/neu and cyclin E in breast cancer. Oncogene. 2010;29:3896-907 pubmed publisher
    b>HER2/neu (HER2) and cyclin E are important prognostic indicators in breast cancer. As both are involved in cell cycle regulation we analyzed whether there was a direct interaction between the two...
  79. Kruger S, Weitsch G, Büttner H, Matthiensen A, Böhmer T, Marquardt T, et al. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Int J Cancer. 2002;102:514-8 pubmed
    The HER2 (c-erbB-2) receptor is overexpressed in a variety of human malignant tumors and, in breast carcinoma, has been identified as a target for anti-HER2-directed therapy with the monoclonal antibody (MAb) trastuzumab...
  80. Hendriks B, Opresko L, Wiley H, Lauffenburger D. Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis: distribution of homo- and heterodimers depends on relative HER2 levels. J Biol Chem. 2003;278:23343-51 pubmed
    ..Many cell types express multiple EGFR family members (including EGFR, HER2, HER3, and/or HER4) that interact to form an array of homo- and heterodimers...
  81. Tubbs R, Barlow W, Budd G, Swain E, Porter P, Gown A, et al. Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status. J Clin Oncol. 2009;27:3881-6 pubmed publisher
    ..We determined the status of the HER2 and TOP2A genes in a large cohort of breast cancer patients treated with adjuvant doxorubicin (A) and ..
  82. Kashihara M, Azuma K, Kawahara A, Basaki Y, Hattori S, Yanagawa T, et al. Nuclear Y-box binding protein-1, a predictive marker of prognosis, is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non-small cell lung cancer. J Thorac Oncol. 2009;4:1066-74 pubmed publisher
    ..In the five NSCLC cell lines, expressions of EGFR, human epidermal growth factor receptor 2 (HER2), HER3, and hepatocyte growth factor receptor (c-Met) in PC-9 cells; of HER2 and c-Met in ..
  83. Helmke B, Zahel T, Breinig M, Schirmacher P, Aulmann S, Kern M. Her2 overexpression is a rare event in anorectal melanoma. Melanoma Res. 2010;20:431-4 pubmed publisher
    ..Tyrosin kinase receptors such as Her2 and EGFR have been awarded a large role in this context...
  84. Epis M, Barker A, Giles K, Beveridge D, Leedman P. The RNA-binding protein HuR opposes the repression of ERBB-2 gene expression by microRNA miR-331-3p in prostate cancer cells. J Biol Chem. 2011;286:41442-54 pubmed publisher
  85. Frank B, Hemminki K, Wirtenberger M, Bermejo J, Bugert P, Klaes R, et al. The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk. Carcinogenesis. 2005;26:643-7 pubmed
    Overexpression of the proto-oncogene ERBB2 (HER2/NEU) has been observed in 20-30% of breast cancers involving poor prognosis. Genetic alterations within ERBB2 have been shown to induce carcinogenesis and metastasis...
  86. Kim Y, Won Y, Park K, Song B, Kim J, Oh S, et al. Prognostic significance of HER2 gene amplification according to stage of breast cancer. J Korean Med Sci. 2008;23:414-20 pubmed publisher
    It is well known that the amplification of the HER2 gene is closely associated with poor prognosis of breast cancer. However, there is controversy about the clinical significance of HER2 according to lymph node status in breast cancer...
  87. Kim K, Koh Y, Chang H, Kim T, Yook J, Kim B, et al. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol. 2011;18:2833-40 pubmed publisher
    Recent advances in molecular targeted therapy have identified HER2 as an important target for anti-cancer therapy in gastric cancer (GC)...
  88. Anastasi S, Sala G, Huiping C, Caprini E, Russo G, Iacovelli S, et al. Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin. Oncogene. 2005;24:4540-8 pubmed
    ..Thus, loss of RALT expression cooperates with ERBB2 gene amplification to drive full oncogenic signalling by the ErbB-2 receptor. Moreover, loss of RALT signalling may adversely affect tumor responses to ErbB-2-targeting agents. ..
  89. Millikan R, Hummer A, Wolff M, Hishida A, Begg C. HER2 codon 655 polymorphism and breast cancer: results from kin-cohort and case-control analyses. Breast Cancer Res Treat. 2005;89:309-12 pubmed
    ..epidemiologic studies show increased breast cancer risk for carriers of the Val-allele at codon 655 of the HER2 gene...
  90. Cox D, Hankinson S, Hunter D. The erbB2/HER2/neu receptor polymorphism Ile655Val and breast cancer risk. Pharmacogenet Genomics. 2005;15:447-50 pubmed
    The erbB2 (HER2/neu) gene is found amplified in tumours. A single nucleotide polymorphism at codon 655 (Ile655Val) has been studied in a number of case-control studies with respect to breast cancer risk, with conflicting results...
  91. Li C, Sun Y, Fang R, Han X, Luo X, Wang R, et al. Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains. J Thorac Oncol. 2012;7:85-9 pubmed publisher
    A fraction of lung adenocarcinomas harbor activating mutations in the HER2 kinase domain. HER2-targeted therapies have shown minimal benefit in molecularly unselected patients...